What your oncologists can learn about prostate cancer this fall

For a glimpse into what your oncologist can learn about prostate cancer this fall check out the agenda for this October 31, 2009 conference. Unfortunately, for prostate cancer this learning session reflects no rapid advancements in standard of care. But if your oncologist falls beneath this standard, find someone better:

Sixth Annual Current Trends in Genitourinary Malignancies

This activity is presented by Physicians’ Education Resource in conjunction with NewYork-Presbyterian, The University Hospital of Columbia and Cornell.

This educational program is directed toward medical oncologists, surgical oncologists, radiation oncologists, urologists, internal medicine and primary care physicians, and basic research investigators interested in the treatment and management of patients with kidney, bladder, and prostate cancers. Fellows, oncology nurses, oncology physician assistants, and pharmacists interested in the treatment of genitourinary malignancies are also invited to attend.

Learning Objectives

At the conclusion of this symposium, you should be able to:

  • Discuss the role of androgen receptors and genetic defects in the progression of prostate cancer
  • Explain the biological basis underlying the predisposition of prostate cancer to metastasize to bone, and discuss the use of bone-targeted therapeutic agents
  • Integrate updated concepts for multimodality treatment, including hormonal therapy, chemotherapy, radiation therapy and surgery, into the management of patients with localized and high risk prostate cancer
  • Apply appropriate taxane-based chemotherapy for the management of hormone refractory prostate cancer
  • Evaluate the role of cytotoxic agents that inhibit the cell cycle and novel agents that target the tumor vasculature or the endothelin signaling system in the treatment of hormone refractory prostate cancer
  • Assess the role of investigational treatment regimens and novel agents in the treatment of genitourinary malignancies
  • Select appropriate patients for enrollment on clinical trials

Above is edited to zero in on prostate cancer content.
LINK: full details at Physician's Education Resource